AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (45)

Latest Posts

About This Stock More About This Stock
Beijing-Based BeiGene Study Of PD-1 Antibody For Patients With Relapsed Or Refractory Hodgkin Lymphoma Underway
Article By: Lorimer Wilson
Sunday, April 23, 2017 1:47 AM EDT
Beijing-based BeiGene has dosed their first patient with refractory classical Hodgkin lymphoma — or cHL — in their Phase I PD-1 checkpoint trial of the drug BGB-A317 in a pivotal study which started less then four months ago.
In this article: BGNE Also: AZN, BMY, MRK, PFE, RHHBY, INCY, AGEN, TGTX
Read
Valeant's $3,500 Sticker On Siliq Could Trigger A Pricing War With Lilly, Novartis
Article By: Lorimer Wilson
Saturday, April 22, 2017 11:20 AM EDT
Valeant Pharmaceuticals, one of the most obvious price-hiking offenders of the last couple of years, has just unveiled the sticker on its new psoriasis drug, Siliq—and it’s the lowest in the market for next-gen meds.
In this article: VRX Also: AZN, JNJ, NVS, AMGN, ESRX, ABBV, LLY
Read
Tocagen IPO Could Garner Significant Investor Attention
Article By: Don Dion
Wednesday, April 12, 2017 4:50 AM EDT
Tocagen Inc. is set to price its IPO today, the company plans to offer 7.25 million shares at an expected price range of $10-12. Tocagen's lead products are in Phase 2/3 of development.
In this article: TOCA Also: AZN, BMY, GSK, MRK, PFE, CELG, KITE, ARGS, ADAP
Read
FDA OKs Tesaro’s "Niraparib" For Ovarian Cancer - Major Setback For Myriad Genetics Inc
Article By: Lorimer Wilson
Tuesday, March 28, 2017 11:10 AM EDT
Tesaro, Inc. has been given a broad approval by the FDA for the use of its PARP drug niraparib, which will now be marketed as Zejula as a maintenance therapy for recurrent ovarian cancer which represents a major setback for Myriad Genetics, Inc.
In this article: TSRO, MYGN Also: AZN, CLVS
Read
Merck KGaA And Pfizer Get FDA Approval Of Checkpoint Inhibitor "Avelumab" For Rare Merkel Cell Skin Cancer Therapy
Article By: Lorimer Wilson
Friday, March 24, 2017 10:17 AM EDT
Biopharma partners Merck KGaA and Pfizer came away with their first FDA approval of the checkpoint inhibitor avelumab, making it the fourth drug in this category to make it to the market.
In this article: MRK, PFE Also: AZN, BMY
Read

PARTNER HEADLINES

Latest Tweets for $AZN

No tweets yet!